Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease

Zhewen Ren; Anke Wesselius; Coen D A Stehouwer; Martijn C G J Brouwers

doi:10.1016/j.ecl.2023.01.002

Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease

Endocrinol Metab Clin North Am. 2023 Sep;52(3):459-468. doi: 10.1016/j.ecl.2023.01.002. Epub 2023 Mar 8.

Authors

Zhewen Ren¹, Anke Wesselius², Coen D A Stehouwer³, Martijn C G J Brouwers⁴

Affiliations

¹ Division of Endocrinology and Metabolic Disease, Department of Internal Medicine, Maastricht University Medical Center, P Debyelaan 25, 6229 HX Maastricht, the Netherlands; CARIM School for Cardiovascular Diseases, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands; Laboratory for Metabolism and Vascular Medicine, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands.
² Department of Epidemiology, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands; NUTRIM School for Nutrition and Translational Research in Metabolism Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands.
³ Division of Endocrinology and Metabolic Disease, Department of Internal Medicine, Maastricht University Medical Center, P Debyelaan 25, 6229 HX Maastricht, the Netherlands; Division of General Internal Medicine, Department of Internal Medicine, Maastricht University Medical Centre, P Debyelaan 25, 6229 HX Maastricht, the Netherlands.
⁴ Division of Endocrinology and Metabolic Disease, Department of Internal Medicine, Maastricht University Medical Center, P Debyelaan 25, 6229 HX Maastricht, the Netherlands; CARIM School for Cardiovascular Diseases, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Electronic address: mcgj.brouwers@mumc.nl.

PMID: 37495337
DOI: 10.1016/j.ecl.2023.01.002

Abstract

Both nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) have been associated with incident cardiovascular disease (CVD), independent of confounders. Causality has recently been inferred by Mendelian randomization studies. Although these findings have contributed to current guidelines that recommend screening for and treatment of cardiovascular risk factors, it not yet clear how to position NAFLD/MAFLD in cardiovascular risk estimation scores and, consequently, which treatment targets should be used. This review aims to provide practical tools as well as suggestions for further research in order to effectively prevent CVD events in patients with NAFLD/MAFLD.

Keywords: Cardiovascular disease; Metabolic dysfunction-associated fatty liver disease; Nonalcoholic fatty liver disease; Preventive measures; Treatment.

Publication types

Review

MeSH terms

Cardiovascular Diseases*
Cardiovascular System
Metabolic Diseases*
Non-alcoholic Fatty Liver Disease*